SI9300144A - Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv) - Google Patents

Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv) Download PDF

Info

Publication number
SI9300144A
SI9300144A SI9300144A SI9300144A SI9300144A SI 9300144 A SI9300144 A SI 9300144A SI 9300144 A SI9300144 A SI 9300144A SI 9300144 A SI9300144 A SI 9300144A SI 9300144 A SI9300144 A SI 9300144A
Authority
SI
Slovenia
Prior art keywords
fiau
precursor
metabolite
hepatitis
amount
Prior art date
Application number
SI9300144A
Other languages
English (en)
Slovenian (sl)
Inventor
Dennis W Adair
Kenneth A Smiles
Dannie King
Original Assignee
Oclassen Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oclassen Pharma Inc filed Critical Oclassen Pharma Inc
Publication of SI9300144A publication Critical patent/SI9300144A/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9300144A 1992-04-06 1993-03-25 Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv) SI9300144A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86389092A 1992-04-06 1992-04-06
US95292792A 1992-09-25 1992-09-25
US07/959,004 US5432165A (en) 1992-04-06 1992-10-09 Methods for the treatment of infection caused by Hepatitis B virus (HBV)

Publications (1)

Publication Number Publication Date
SI9300144A true SI9300144A (en) 1994-03-31

Family

ID=27420427

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300144A SI9300144A (en) 1992-04-06 1993-03-25 Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv)

Country Status (26)

Country Link
US (1) US5432165A (it)
EP (1) EP0565412A1 (it)
JP (1) JPH069403A (it)
CN (1) CN1081879A (it)
AP (1) AP372A (it)
AU (1) AU662804B2 (it)
BE (1) BE1009181A5 (it)
BR (1) BR9306207A (it)
CA (1) CA2092356A1 (it)
EE (1) EE9400068A (it)
ES (1) ES2105923B1 (it)
FR (1) FR2689398B1 (it)
GR (1) GR930100111A (it)
IL (1) IL105169A0 (it)
IT (1) IT1264332B1 (it)
LV (1) LV10191B (it)
MD (1) MD940152A (it)
MX (1) MX9301922A (it)
NO (1) NO931246L (it)
NZ (1) NZ247188A (it)
OA (1) OA10102A (it)
PH (1) PH31116A (it)
PT (1) PT101238A (it)
SI (1) SI9300144A (it)
WO (1) WO1993019762A1 (it)
YU (1) YU23993A (it)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346627B1 (en) * 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996010649A1 (en) * 1994-09-30 1996-04-11 Southwest Foundation For Biomedical Research Isolated human hepatitis b virus polymerase and uses thereof
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6296882B1 (en) * 2000-06-12 2001-10-02 Manuel Viamonte, Jr. Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, and lemon oil
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (it) *
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds

Also Published As

Publication number Publication date
ITTO930226A1 (it) 1994-10-05
JPH069403A (ja) 1994-01-18
PT101238A (pt) 1994-03-31
GR930100111A (el) 1993-12-30
BE1009181A5 (fr) 1996-12-03
LV10191B (en) 1995-04-20
ES2105923A1 (es) 1997-10-16
NO931246L (no) 1993-10-07
LV10191A (lv) 1994-10-20
MX9301922A (es) 1993-10-01
PH31116A (en) 1998-02-28
US5432165A (en) 1995-07-11
MD940152A (ro) 1995-12-31
IT1264332B1 (it) 1996-09-23
EE9400068A (et) 1995-12-15
NO931246D0 (no) 1993-03-31
CN1081879A (zh) 1994-02-16
FR2689398A1 (fr) 1993-10-08
NZ247188A (en) 1995-05-26
EP0565412A1 (en) 1993-10-13
AU662804B2 (en) 1995-09-14
ES2105923B1 (es) 1998-07-01
CA2092356A1 (en) 1993-10-07
WO1993019762A1 (en) 1993-10-14
YU23993A (sh) 1997-05-28
FR2689398B1 (fr) 1994-11-18
ITTO930226A0 (it) 1993-04-05
BR9306207A (pt) 1998-06-23
AP372A (en) 1994-11-24
AU3530293A (en) 1993-10-07
AP9300513A0 (en) 1993-04-30
OA10102A (en) 1996-12-18
IL105169A0 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
Boucher et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus
Keeney et al. Acyclovir tolerance in humans
Bernardi et al. Effects of prolonged ingestion of graded doses of licorice by healthy volunteers
SI9300144A (en) Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv)
US4415590A (en) Herpes treatment
US5055457A (en) Pharmaceutical combinations product and the preparation and use thereof
AU2007223901A1 (en) Use of VX-702 for treating rheumatoid arthritis
NL194430C (nl) Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
EA001099B1 (ru) Инъекционное лекарственое средство "цитофлавин", обладающее цитопротекторным действием
SK42593A3 (en) Antitusic agents
Matthews et al. Zidovudine and Other Reverse Transcriptase Inhibitors in the Management of Human Immunodeficiency Virus‐Related Disease
Kolski et al. The Use of Theophylline Clearance in Pediatric Status Asthmaticus: I. Interpatient and Intrapatient Theophylline Clearance Variability
Lambert et al. Didanosine: long-term follow-up of patients in a phase 1 study
JPH06500129A (ja) ヌクレオシド誘導体
JP3096052B2 (ja) 脂質代謝調節剤
JP2002542283A (ja) 医薬処方物
JPH0219804B2 (it)
US6040298A (en) Methods for treatment with compositions effective against acyclovir-resistant strains of herpes viruses
JP2603359B2 (ja) 抗血栓剤
Reis et al. Antivirals
Sansom The Influence of Food on the Bioavailability of a Sustained Release Theophylline Formulation
JP2008534521A (ja) ピリドキサール5’−リン酸の静脈用製剤、調製方法、およびその使用
JPH09104632A (ja) 血管増強剤
JPH01502666A (ja) 閉塞性気道疾患の治療のための製剤
WO1995011027A1 (en) Use of peniclorin for the treatment of posttherapeutic neuralgia